FDA should reconsider capital costs of AERs: CRN
The Food & Drug Administration’s (FDA) position that dietary supplement adverse event reporting incurs no capital costs or operating and maintenance costs is wrong and should be reconsidered, says the Council for Responsible Nutrition (CRN).